pipeline

AstraZeneca ($AZN) reported Q1 revenue of $15.29B, up 13% YoY, with oncology surging 20%. Shares fell 2.30% despite beating estimates.

Enbridge, Enterprise Products, and Chevron offer 5.4%, 5.8%, and 3.8% yields respectively, backed by 31, 27, and 39-year dividend increase streaks.

Energy Transfer trades under $20 with a 11.3 forward P/E, positioned to capitalize on data center expansion and rising natural gas demand through existing Oracle and Entergy deals.

Biogen's three-decade outperformance is challenged by biosimilar competition and weak growth, though new Alzheimer's and rare disease drugs offer hope. Success requires flawless execution.

$ENB trades 12% below $85 CAD target with 5.2% dividend yield, 31-year increase streak, and attractive 13-14x DCF valuation.

Ardelyx appoints Dr. Rajani Dinavahi, veteran biotech executive from Amgen and Atara Biotherapeutics, as Chief Medical Officer to lead clinical strategy and pipeline advancement.

Energy Transfer thrives in any oil price scenario through its fee-based midstream model (90% of earnings). Offers 6.3% dividend yield and natural gas infrastructure upside.

MPLX LP offers 7.3% dividend yield with $5.8B annual cash flow, insulated from oil volatility through fee-based midstream operations and 1.4x coverage ratio.

Vertex Pharmaceuticals trails broader market but boasts promising pipeline candidates in kidney disease and diabetes, positioning potential recovery.

Eli Lilly dominates weight management, Vertex controls cystic fibrosis, and Pfizer offers undervalued shares with 6.3% dividend yield.

Mesoblast Limited will host inaugural R&D Day April 8, 2026 in NYC, featuring Ryoncil commercialization updates and new cellular medicine technology.

Orexo invites investors to March 24 R&D Day in Stockholm to present post-Zubsolv strategy, featuring AmorphOX technology and pipeline programs OX640 and OX390.

Merck restructures commercial operations into two divisions ahead of Keytruda's 2028 patent expiration, aiming to accelerate growth from 20+ pipeline candidates.

Iovance's newly approved melanoma therapy Amtagvi generated $68M in quarterly revenue with strong 52% response rates, positioning the biotech for pipeline expansion across multiple cancer indications.